WO2011000945A3 - Aminoalcamides pour une utilisation dans le traitement de maladies inflammatoires, dégénératives ou démyélinisantes du système nerveux central - Google Patents

Aminoalcamides pour une utilisation dans le traitement de maladies inflammatoires, dégénératives ou démyélinisantes du système nerveux central Download PDF

Info

Publication number
WO2011000945A3
WO2011000945A3 PCT/EP2010/059471 EP2010059471W WO2011000945A3 WO 2011000945 A3 WO2011000945 A3 WO 2011000945A3 EP 2010059471 W EP2010059471 W EP 2010059471W WO 2011000945 A3 WO2011000945 A3 WO 2011000945A3
Authority
WO
WIPO (PCT)
Prior art keywords
degenerative
cns
inflammatory
aminoalkamides
treatment
Prior art date
Application number
PCT/EP2010/059471
Other languages
English (en)
Other versions
WO2011000945A9 (fr
WO2011000945A2 (fr
Inventor
Nicholas Kelly
Anja Wellejus
Signe Humle JØRGENSEN
Morten Sloth Weidner
Original Assignee
Nensius Research A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nensius Research A/S filed Critical Nensius Research A/S
Publication of WO2011000945A2 publication Critical patent/WO2011000945A2/fr
Publication of WO2011000945A3 publication Critical patent/WO2011000945A3/fr
Publication of WO2011000945A9 publication Critical patent/WO2011000945A9/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

L'invention porte sur un aminoalcamide de la formule I pour une utilisation en tant que médicament pour traiter des maladies inflammatoires, dégénératives ou démyélinisantes du système nerveux central chez un sujet en ayant besoin.
PCT/EP2010/059471 2009-07-03 2010-07-02 Aminoalcamides pour une utilisation dans le traitement de maladies inflammatoires, dégénératives ou démyélinisantes du système nerveux central WO2011000945A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP09164583 2009-07-03
EP09164583.8 2009-07-03
US22311109P 2009-07-06 2009-07-06
US61/223,111 2009-07-06

Publications (3)

Publication Number Publication Date
WO2011000945A2 WO2011000945A2 (fr) 2011-01-06
WO2011000945A3 true WO2011000945A3 (fr) 2011-02-24
WO2011000945A9 WO2011000945A9 (fr) 2011-04-07

Family

ID=41136872

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/059471 WO2011000945A2 (fr) 2009-07-03 2010-07-02 Aminoalcamides pour une utilisation dans le traitement de maladies inflammatoires, dégénératives ou démyélinisantes du système nerveux central

Country Status (2)

Country Link
TW (1) TW201113280A (fr)
WO (1) WO2011000945A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2968508B1 (fr) * 2010-12-09 2013-01-04 Crea Dispositif pyrotechnique a mise a feu securisee
US10577357B2 (en) 2016-09-19 2020-03-03 The Texas A&M University System Inhibitors of LDLR-PCSK9 protein-protein interaction and methods of their use
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
TW202027794A (zh) 2018-10-03 2020-08-01 瑞士商諾華公司 血管生成素樣３多肽之持續遞送

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2702537A1 (de) * 1976-01-23 1977-07-28 Corvi Camillo Spa Neue piperazinderivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
EP0582164A1 (fr) * 1992-07-31 1994-02-09 Bristol-Myers Squibb Company Dérivés de diphényl oxazoles, thiazoles et imidazoles comme inhibiteurs de la réabsorption d'adénosine
WO1996032386A1 (fr) * 1995-04-14 1996-10-17 Boehringer Ingelheim Kg Derives d'arylglycinamides, procede de fabrication et compositions pharmaceutiques contenant ces composes
WO2000008006A2 (fr) * 1998-08-07 2000-02-17 Eli Lilly And Company Limited Composes pharmaceutiques
WO2006018188A2 (fr) * 2004-08-17 2006-02-23 F. Hoffmann-La Roche Ag Hydantoines substituees

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1150759B (it) 1982-04-05 1986-12-17 Corvi Camillo Spa Complessi organometallici di n-cicloesil-piperazino-acetammidi o propionammidi, loro preparazione e impiego come farmaci antiulcera-antisecretivi-tamponanti
EP0585500A1 (fr) 1992-09-04 1994-03-09 Merrell Dow Pharmaceuticals Inc. Diaryl préperazinacétamide comme agents antimuscariniques
KR20010013387A (fr) 1997-06-16 2001-02-26 디르크 반테 Utilisation d'analogues de draflazine dans le traitement de la douleur
ATE313534T1 (de) 2001-02-16 2006-01-15 Aventis Pharma Inc Heterocyclische substituierte carbonyl derivate und ihre verwendung als dopamin d3 rezeptor liganden

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2702537A1 (de) * 1976-01-23 1977-07-28 Corvi Camillo Spa Neue piperazinderivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
EP0582164A1 (fr) * 1992-07-31 1994-02-09 Bristol-Myers Squibb Company Dérivés de diphényl oxazoles, thiazoles et imidazoles comme inhibiteurs de la réabsorption d'adénosine
WO1996032386A1 (fr) * 1995-04-14 1996-10-17 Boehringer Ingelheim Kg Derives d'arylglycinamides, procede de fabrication et compositions pharmaceutiques contenant ces composes
WO2000008006A2 (fr) * 1998-08-07 2000-02-17 Eli Lilly And Company Limited Composes pharmaceutiques
WO2006018188A2 (fr) * 2004-08-17 2006-02-23 F. Hoffmann-La Roche Ag Hydantoines substituees

Also Published As

Publication number Publication date
WO2011000945A9 (fr) 2011-04-07
TW201113280A (en) 2011-04-16
WO2011000945A2 (fr) 2011-01-06

Similar Documents

Publication Publication Date Title
HRP20130357T1 (en) Novel compounds useful for the treatment of degenerative and inflammatory diseases.
WO2012062925A3 (fr) Composés et procédés de traitement de la douleur
MX2010002312A (es) Compuestos de triazolopiridina y su uso como inhibidores de cinasa reguladora de señal de apoptosis.
WO2012024620A3 (fr) Inhibiteurs de l'autotaxine et leurs utilisations
MY160241A (en) 5-alkynyl-pyrimidines
IL219610A (en) Preparations containing a history of 3-hydroxy-2-oxo-1,2-dihydropyridine for use in the treatment or preparation of a drug for the treatment of epithelial tissue inflammation
AP2010005508A0 (en) Triazole derivatives useful for the treatment of diseases.
MX2011011854A (es) Dihidropirimidinonas para uso como inhibidores de la bace2.
WO2013098416A3 (fr) Composes anti-douleur
ZA201401678B (en) Novel distributed 3,4-diamino-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases
WO2010150211A3 (fr) Utilisation de dérivés d'indoles dans le traitement du cancer
IL211313A0 (en) Compounds, compositions and methods for the treatment of ??-amyloid diseases and synucleinopathies
WO2012104823A3 (fr) Composés pyridopyrimidinones dans le traitement de maladies neurodégénératives
WO2009074247A8 (fr) Nouveaux dérivés d'amide d'acide 2-arylthiazole-4-carboxylique, leur préparation et leur utilisation en tant que médicament
WO2012024282A3 (fr) Composés de 1,5-diphényl-penta-1,4-dién-3-one
WO2009124962A3 (fr) Sulfonamides
WO2010119102A3 (fr) Préparation pharmaceutique pour le traitement de maladies dermatologiques auto-immunes
MX2010009837A (es) Tiazolil-dihidro-indazoles.
WO2011000945A3 (fr) Aminoalcamides pour une utilisation dans le traitement de maladies inflammatoires, dégénératives ou démyélinisantes du système nerveux central
EP2488507A4 (fr) Nouveaux inhibiteurs de mek, utiles dans le traitement des maladies
UA103197C2 (uk) Застосування ніфуртимоксу для лікування хвороб, спричинених трихомонадами
WO2010004031A3 (fr) Traitement inédit
WO2011009987A3 (fr) Dérivés d'acides auréoliques, leur procédé d'obtention et leurs utilisations
WO2009151495A3 (fr) Composés oxazoles, compositions et procédés d'utilisation
WO2008037497A3 (fr) Utilisations de la galectine-2

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10734713

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10734713

Country of ref document: EP

Kind code of ref document: A2